An observational study in Obesity and Obesity-related Medical Conditions, Obesity and Overweight and Insulin Sensitivity/Resistance, sponsored by ETH Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by ETH Zurich · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Obesity with a site in Switzerland — 22 open to participants now, 30 under way, 5 of them phase 3. Obesity · Switzerland.
Among the 127 studies in Obesity with a site in Switzerland, this one is the 25th largest by enrollment of the 37 observational ones that give a count, is one of 9 that started in 2025, is one of 37 observational ones, and was the 115th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →22 of the 127 studies in Obesity with a site in Switzerland are open now. Recruiting first, the newest first:
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Amgen · Sites in Switzerland, United States, Argentina and 32 more countries
Ages 18–99
University Hospital, Geneva · Sites in Switzerland
Ages 45–60 · Women only
University of Zurich · Sites in Switzerland
Ages 18–50 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 64 across the 90 interventional studies, 85 across the 37 observational. Of the 85 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 127 have an industry lead sponsor. The 10 most frequent:
ETH Zurich is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
ETH Zurich has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
10 of the studies in Obesity with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT04234373University Hospital, Basel, SwitzerlandEffect of a Low-carb Dietary Intervention in Obese Patients: a Pilot Trial | 2026-12 |
| NCT02902198University Hospital, Basel, SwitzerlandTaste Physiology in Obese Volunteers Before and After Bariatric Surgery | 2026-12 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 127 studies in Obesity with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.
The TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.
The investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.
A total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.
The investigators plan to include a total of 40 non-diabetic, obese individuals that will undergo treatment with semaglutide as a weight-loss intervention independent of our observational study. To avoid a highly heterogeneous participant group, inclusion in the study will be limited to individuals with a BMI between 30 and 40 kg/m². Patients with a prediabetic state will not be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
30 - 40 kg/m2
a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg/m2
Exclusion Criteria:
Pregnancy or active breast feeding
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-diabetic obese individuals with planned semaglutide treatment as a weight loss intervention
This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Change in body weight (%)
Time frame: 16 weeks
Change in fat mass (%)
measured by DEXA (dual energy x-ray absorptiometry)
Time frame: 16 weeks
Change in lean mass (%)
measured by DEXA
Time frame: 16 weeks
Change in abdominal visceral fat area (in cm2)
measured by DEXA
Time frame: 16 weeks
Change in cell size of adipose tissue after 16 weeks of semaglutide treatment
The size of adipocytes is a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations.
Time frame: 16 weeks
Changes in cell distribution of adipose tissue after 16 weeks of semaglutide treatment
Changes in the distribution of adipocytes and other components of adipose tissue (e.g. macrophages, progenitors) serve as a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations.
Time frame: 16 weeks
Changes in signs of fibrosis in adipose tissue after 16 weeks of semaglutide treatment
Signs of fibrosis are a direct measure of adipose tissue quality and function. They will be evaluated through histopathological analysis.
Time frame: 16 weeks
Changes in inflammatory activity of adipose tissue after 16 weeks of semaglutide treatment
Inflammatory activity, measured by the number and type of white blood cells infiltrating adipose tissue, is a direct way to assess adipose tissue quality and function. It will be evaluated by quantifying inflammatory cells within the tissue.
Time frame: 16 weeks
Change in adipokine secretion pattern after 16 weeks of semaglutide treatment
The adipokine-secretion pattern is an indirect way to assess adipose tissue quality and function. We will analyze leptin, adipokines, and other relevant markers in blood samples and potentially in adipose tissue from strong or weak responders to identify patterns that may help predict significant changes or the absence of response.
Time frame: 16 weeks
Change in systemic inflammation after 16 weeks of semaglutide treatment
Adipose tissue dysfunction can contribute to systemic inflammation, making it an indirect measure of adipose tissue quality. Serum levels of systemic inflammatory markers such as C-reactive protein (CRP), interleukins, and tumor necrosis factor-alpha (TNF-α) will be assessed before and after 16 weeks of semaglutide treatment.
Time frame: 16 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Sep 2026, 17 months.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's 17 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ETH Zurich